Abstract:Background: Eosinophilic esophagitis (EoE) is a clinicopathologic disorder first described in 1978 which has gained significant recognition over the past 10 years. Numerous prevalence studies have been performed around the globe, both in pediatric and adult populations documenting a prevalence between 0.002% and 6.5%. The aim of this study is to assess the utility of routinely screening for EoE in patients with dysphagia. Methods: A prospective, observational study in which adult patients with a complaint of esophageal dysphagia were enrolled. Results: Of the 135 patients enrolled, 122 completed the study; 100 patients had nonobstructive dysphagia, while 22 patients had a luminal finding which could explain their dysphagia. The prevalence of EoE in the nonobstructive dysphagia group was 22% (95% CI: 13.930.1%); 32.7% of male patients with nonobstructive dysphagia were found to have EoE compared with 8.9% of females (p ¼ 0.004). The mean age of nonobstructive patients found to have EoE was 37.8 years. White patients with nonobstructive dysphagia were found to have a 25.9% prevalence of EoE, compared with 0% of African Americans, 0% of Asians, and 14.3% of Hispanics. When comparing Whites with non-Whites, the prevalence of EoE was noted to be 25.9% versus 5.3%, respectively (p ¼ 0.050). Conclusions: EoE is a common cause of nonobstructive dysphagia. We believe that the high prevalence of EoE in patients with nonobstructive dysphagia supports the practice of routine biopsies to screen for the presence of abnormally high numbers of eosinophils in this subgroup.

No abstract

Drug-induced liver injury (DILI) is the leading cause of acute hepatic failure in the United States. Up to 13% of acute liver failure cases occur due to drugs other than acetaminophen. This clinical diagnosis, made after other causes of liver injury have been excluded, requires establishing a causal relationship between drug exposure and liver injury. The case of a patient with liver injury following a subcutaneous histrelin (Vantus) implant as therapy for advanced prostate cancer is presented.

No abstract

No abstract